311 related articles for article (PubMed ID: 38542872)
1. Inhibitors of Cyclophilin A: Current and Anticipated Pharmaceutical Agents for Inflammatory Diseases and Cancers.
Zhao X; Zhao X; Di W; Wang C
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542872
[TBL] [Abstract][Full Text] [Related]
2. Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity.
Chen S; Zhao X; Tan J; Lu H; Qi Z; Huang Q; Zeng X; Zhang M; Jiang S; Jiang H; Yu L
Eur J Pharmacol; 2007 Jun; 565(1-3):54-9. PubMed ID: 17449029
[TBL] [Abstract][Full Text] [Related]
3. Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication.
Ma-Lauer Y; Zheng Y; Malešević M; von Brunn B; Fischer G; von Brunn A
Antiviral Res; 2020 Jan; 173():104620. PubMed ID: 31634494
[TBL] [Abstract][Full Text] [Related]
4. Cyclophilin A: a key player for human disease.
Nigro P; Pompilio G; Capogrossi MC
Cell Death Dis; 2013 Oct; 4(10):e888. PubMed ID: 24176846
[TBL] [Abstract][Full Text] [Related]
5. A fluorescence polarization-based assay for peptidyl prolyl cis/trans isomerase cyclophilin A.
Liu Y; Jiang J; Richardson PL; Reddy RD; Johnson DD; Kati WM
Anal Biochem; 2006 Sep; 356(1):100-7. PubMed ID: 16737676
[TBL] [Abstract][Full Text] [Related]
6. Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin.
Bell A; Wernli B; Franklin RM
Biochem Pharmacol; 1994 Aug; 48(3):495-503. PubMed ID: 7520696
[TBL] [Abstract][Full Text] [Related]
7. Non-Immunosuppressive Cyclophilin Inhibitors.
Schiene-Fischer C; Fischer G; Braun M
Angew Chem Int Ed Engl; 2022 Sep; 61(39):e202201597. PubMed ID: 35290695
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity.
Hong F; Lee J; Song JW; Lee SJ; Ahn H; Cho JJ; Ha J; Kim SS
FASEB J; 2002 Oct; 16(12):1633-5. PubMed ID: 12207006
[TBL] [Abstract][Full Text] [Related]
9. Structural and biochemical characterization of the cytosolic wheat cyclophilin TaCypA-1.
Sekhon SS; Kaur H; Dutta T; Singh K; Kumari S; Kang S; Park SG; Park BC; Jeong DG; Pareek A; Woo EJ; Singh P; Yoon TS
Acta Crystallogr D Biol Crystallogr; 2013 Apr; 69(Pt 4):555-63. PubMed ID: 23519664
[TBL] [Abstract][Full Text] [Related]
10. Cyclophilin A as a target of Cisplatin chemosensitizers.
Hamilton G
Curr Cancer Drug Targets; 2014; 14(1):46-58. PubMed ID: 24200080
[TBL] [Abstract][Full Text] [Related]
11. Solution structure of the cyclosporin A/cyclophilin complex by NMR.
Thériault Y; Logan TM; Meadows R; Yu L; Olejniczak ET; Holzman TF; Simmer RL; Fesik SW
Nature; 1993 Jan; 361(6407):88-91. PubMed ID: 8421500
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity.
Nevers Q; Ruiz I; Ahnou N; Donati F; Brillet R; Softic L; Chazal M; Jouvenet N; Fourati S; Baudesson C; Bruscella P; Gelin M; Guichou JF; Pawlotsky JM; Ahmed-Belkacem A
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760125
[TBL] [Abstract][Full Text] [Related]
13. [Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors].
Tian L; Liu W; Sun L
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):605-611. PubMed ID: 32347055
[TBL] [Abstract][Full Text] [Related]
14. Transgenic mice overexpressing cyclophilin A are resistant to cyclosporin A-induced nephrotoxicity via peptidyl-prolyl cis-trans isomerase activity.
Hong F; Lee J; Piao YJ; Jae YK; Kim YJ; Oh C; Seo JS; Yun YS; Yang CW; Ha J; Kim SS
Biochem Biophys Res Commun; 2004 Apr; 316(4):1073-80. PubMed ID: 15044094
[TBL] [Abstract][Full Text] [Related]
15. The novel cyclophilin inhibitor C105SR reduces hepatic ischaemia-reperfusion injury via mitoprotection.
Kheyar A; Ahnou N; Ahmed-Belkacem A; Hulin A; Pressiat C; Ghaleh B; Guichou JF; Morin D; Pawlotsky JM; Teixeira-Clerc F
JHEP Rep; 2023 Nov; 5(11):100876. PubMed ID: 37860051
[TBL] [Abstract][Full Text] [Related]
16. The N-terminal cyclophilin-homologous domain of a 150-kilodalton tumor recognition molecule exhibits both peptidylprolyl cis-trans-isomerase and chaperone activities.
Rinfret A; Collins C; Ménard R; Anderson SK
Biochemistry; 1994 Feb; 33(7):1668-73. PubMed ID: 7906541
[TBL] [Abstract][Full Text] [Related]
17. Role of CypA and Hsp90 in membrane translocation mediated by anthrax protective antigen.
Dmochewitz L; Lillich M; Kaiser E; Jennings LD; Lang AE; Buchner J; Fischer G; Aktories K; Collier RJ; Barth H
Cell Microbiol; 2011 Mar; 13(3):359-73. PubMed ID: 20946244
[TBL] [Abstract][Full Text] [Related]
18. The mutant Escherichia coli F112W cyclophilin binds cyclosporin A in nearly identical conformation as human cyclophilin.
Fejzo J; Etzkorn FA; Clubb RT; Shi Y; Walsh CT; Wagner G
Biochemistry; 1994 May; 33(19):5711-20. PubMed ID: 8180197
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of anoxia-induced injury in heart myocytes by cyclosporin A.
Nazareth W; Yafei N; Crompton M
J Mol Cell Cardiol; 1991 Dec; 23(12):1351-4. PubMed ID: 1811053
[TBL] [Abstract][Full Text] [Related]
20. The three-dimensional structure of two redox states of cyclophilin A from Schistosoma mansoni. Evidence for redox regulation of peptidyl-prolyl cis-trans isomerase activity.
Gourlay LJ; Angelucci F; Baiocco P; Boumis G; Brunori M; Bellelli A; Miele AE
J Biol Chem; 2007 Aug; 282(34):24851-7. PubMed ID: 17591771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
